Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Orphan Star Therapeutics

Request full access

ANYC-based biopharmaceutical company

New York City, United StatesHealth

About Orphan Star Therapeutics

Orphan Star Therapeutics, LLC is a biopharmaceutical company founded in 2017 by Dr. Nick France, who also serves as the CEO. The company operates out of New York City and is dedicated to creating treatments for rare diseases. Specifically, their focus is on rare genetic and neurometabolic diseases, with Canavan Disease and GluT1 deficiency being key areas of interest. Canavan Disease is a severe genetic neurodegenerative disorder that typically results in fatality within the first decade of a patient's life.

The company's business model revolves around advancing an early-stage pipeline of drug candidates. In September 2018, Orphan Star Therapeutics announced it had secured a $20 million commitment from a commercial pharmaceutical partner to fund these efforts. This capital is intended to advance their pipeline and to acquire promising clinical-stage drug candidates through strategic partnerships with industry and academic institutions. The company aims to expedite the development of targeted treatments that address the root cause of these serious rare disorders.

The company's strategy involves building a portfolio of early-stage drug candidates for these rare conditions. While the full product pipeline has not been publicly disclosed, the initial focus on Canavan Disease highlights their commitment to addressing significant unmet medical needs. To support its mission, Orphan Star has assembled a team of experienced professionals and a Scientific Advisory Board with experts in Canavan disease and gene therapy.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
2.0/100
Industry
Health, Kids
Sector
Biotechnology, Hard Tech
Business model
Manufacturing
Client focus
B2C
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Sep 2018 $20M $80M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Orphan Star Therapeutics website traffic

Latest recorded traffic for Orphan Star Therapeutics is 50 monthly website visits.

Latest monthly visits50
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Orphan Star Therapeutics in the New York City ecosystem

Live from Dealroom

The Orphan Star Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · New York City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Orphan Star Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Orphan Star Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.